Intravenous pamidronate therapy in osteogenesis imperfecta: Response to treatment and factors influencing outcome

Journal of Pediatric Orthopaedics

Volumn 27, Issue 2, 2007, Pages 225-227

  Bajpai, Anurag ^b   Kabra, Madhulika ^a   Gupta, Neerja ^a   Sharda, Sheetal ^a   Ghosh, Manju ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

Osteogenesis imperfecta; Outcome; Pamidronate

Indexed keywords

CALCIUM CARBONATE; PAMIDRONIC ACID; PARACETAMOL;

ARTICLE; BONE DENSITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; FEVER; FOLLOW UP; FRACTURE; HUMAN; HYPOCALCEMIA; LIVER DYSFUNCTION; MULTIPLE CYCLE TREATMENT; OPEN STUDY; OSTEOGENESIS IMPERFECTA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TOXIC HEPATITIS; TREATMENT DURATION;

BONE DENSITY CONSERVATION AGENTS; CHILD, PRESCHOOL; DIPHOSPHONATES; HUMANS; OSTEOGENESIS IMPERFECTA; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33847227271     PISSN: 02716798     EISSN: None     Source Type: Journal    
DOI: 10.1097/bpo.0b013e3180316d06     Document Type: Article

References (16)

1. Paterson CR. Osteogenesis imperfecta and other heritable disorders of bone. Ballieres Clin Endocrinol Metab. 1997;11:195-213.
2. Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979;16:101-116.
3. Cattell HS, Clayton B. Failure of anabolic steroids in the therapy of osteogenesis imperfecta: a clinical, metabolic and biochemical study. J Bone Joint Surg Am. 1968;50:123-141.
4. Pedersen U, Charles P, Hansen HH, et al. Lack of effects of human calcitonin in osteogenesis imperfecta. Acta Orthop Scand. 1985;56:260-264.
5. Castells S. New approaches to treatment of osteogenesis imperfecta. Clin Orthop Relat Res. 1973;93:239-249.
6. Glorieux FH, Travers R, Chabot G, et al. Bone histomorphometric analysis in osteogenesis imperfecta. J Bone Miner Res. 1994;9(suppl 1):226. [abstract].
7. Astrom E, Soderhall S. Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta. Acta Paediatr. 1998;87:64-68.
8. Glorieux FH, Bishop NJ, Plotkin H, et al. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998;339:947-952.
9. Rauch F, Plotkin H, Zeitlin L, et al. Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy. J Bone Miner Res. 2003;18:610-614.
10. Falk MJ, Heeger S, Lynch KA, et al. Intravenous bisphosphonate therapy in children with osteogenesis imperfecta. Pediatrics. 2003;111:573-578.
11. Astrom E, Soderhall S. Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child. 2002;86:356-364.
12. Zacharin M, Kanumakala S. Pamidronate treatment of less severe forms of osteogenesis imperfecta in children. J Pediatr Endocrinol Metab. 2004;17:1511-1517.
13. Letocha AD, Cintas HL, Troendle JF, et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res. 2005;20:977-986.
14. Pizones J, Plotkin H, Parra-Garcia JI, et al. Bone healing in children with osteogenesis imperfecta treated with bisphosphonates. J Pediatr Orthop. 2005;25:332-335.
15. Zacharin M, Bateman J. Pamidronate treatment of osteogenesis imperfecta - lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response. J Pediatr Endocrinol Metab. 2002;15:163-174.
16. Sweid HA, Bagga A, Vaswani M, et al. Urinary excretion of minerals, oxalate and uric acid in north Indian children. Pediatr Nephrol. 1997;11:189-192.